
Betadex sulfobutyl ether sodium
Subcategory:
Pharmaceutical Cyclodextrin
Product Information:
Product Name:BETADEX SULFOBUTYL ETHER SODIUM
Quality standard: USP-NF2023, EP10.3, enterprise standard
Appearance: white powder
CAS NO.:182410-00-0
Molecular formula:C42H70-nO35(C4H8SO3Na)n , n is the degree of substitution
Molecular weight:1134+158n
Product features and applications
Betadex Sulfobutyl Ether Sodium, also known as sulfobutyl ether betacyclodextrin sodium salt, is the sodium salt of betacyclodextrin alkylated by 1,4-butanesulfonolactone under alkaline conditions, is an anionic, highly water-soluble cyclodextrin derivatives, which can be very well encapsulated with the drug molecules to form a non-covalent complex, thus improving the stability of the drug, water solubility, safety, reducing nephrotoxicity, moderating the hemolysis of the drug, controlling the release of the drug rate, masking bad odor, etc.
Route of administration】:Injection, oral, nasal, ophthalmic, with special affinity and encapsulation for nitrogen-containing drugs.
Product Performance:
1. Solubilization:
Neutral, positive and negative APIs can be effectively combined with sulfobutyl betacyclodextrin, so that the solubility of compounds with different solubility in API water can be increased by 10 to 25,000 times.
2. Convenient drug delivery:
Sulfobutylbeta cyclodextrin has good biocompatibility and can be administered by injection, oral, ocular, nasal, topical and inhalation.
3. Good safety:
Normally its elimination from the kidneys is rapid and complete after administration. In vitro experiments and in vivo acute, subacute and chronic toxicity studies provide safe data and approved for use in human pharmaceutical preparations.
4. Good Stability:
Interaction with sulfobutyl betacyclodextrin can provide a beneficial protective environment for the API in its lipophilic cavity, while the hydrophilic surface provides excellent water solubility providing solubility and stability.
Testing Standards:
Test items | Statutory standard(USP-NF2023) | |
Appearance | White or off-white amorphous powder | |
Solubility | It is soluble in water, slightly soluble in methanol, almost insoluble in ethanol, hexane, n-butane, acetonitrile, isopropanol and ethyl acetate. | |
Appraise | Infrared Spectroscopy | Same absorption band as the standard |
Liquid phase (chemistry) | The retention time of the main peak of the sample solution should be the same as that of the standard solution. | |
Average substitution | should comply with regulations | |
Na | Sodium salt reaction | |
Content | 95.0%-105.0% | |
Aqueous solution pH | 30% w/v aqueous solution pH 4.0-6.8 | |
Heavy metal | ≤5ppm | |
Betacyclodextrin | ≤0.1% | |
1,4-Butanesulfonolactone | ≤0.5ppm | |
NaCl | ≤0.2% | |
4-Hydroxybutane-1-sulfonic acid | ≤0.09% | |
Disodium bis(4-sulfobutyl) ether | ≤0.05% | |
Bacterial endotoxin | ≤10Eu/g | |
Total aerobic bacteria | ≤100cfu/g | |
Total Molds and Yeasts | ≤50cfu/g | |
Escherichia coli (E. coli) | Not detectable | |
Solution Clarity | The 30% (W/V) solution was clarified. | |
Average substitution | 6.2-6.9 | |
Peak (% peak area) | I | 0.0-0.3 |
II | 0.0-0.9 | |
III | 0.5-5.0 | |
IV | 1.0-10.0 | |
V | 10.0-20.0 | |
VI | 15.0-25.0 | |
VII | 20.0-30.0 | |
VIII | 10.0-25.0 | |
IX | 2.0-12.0 | |
X | 0.0-4.0 | |
PH (chemistry) | 4.0-6.8 | |
Moisture content | ≤10.0% | |
Storage conditions | Keep sealed, protected from moisture and at room temperature |
Packaging storage
Packing: in accordance with the pharmaceutical packaging
Packing specification: 1kg/bag; 2kg/bag; 10kg/drum; 20kg/drum
Storage: Sealed and kept in dry place
keyword:
Betadex Sulfobutyl Ether Sodium